Immunogenicity and Safety of a Novel MMR Vaccine (Live) (Freeze-dried): Results of a Phase II Clinical Trial
Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 1
Abstract
ABSTRACT Introduction: This is the first study in Indian paediatric subjects to evaluate the novel Measles, Mumps and Rubella (MMR) vaccine developed by M/s Cadila Healthcare Limited, India, containing the Hoshino mumps strain. This phase II study was done as part of clinical development programme to evaluate the safety and immunogenicity of the novel vaccine in small cohort of target population before conducting the larger comparative phase III study. Aim: To evaluate the immunogenicity and safety of the singledose and multi-dose formulations of the novel vaccine. Materials and Methods: One hundred and twenty three healthy children 15-18 months of age were administered a single dose of the novel MMR vaccine from either the single-dose or the multi-dose formulation. Immunogenicity of the vaccine was assessed by measuring IgG antibodies against the measles, mumps and rubella viruses before and six weeks after the vaccination. Safety of the vaccine was assessed by recording adverse events during the six week study period. Results: The seroconversion rate for anti-measles and antimumps antibodies was 100% while that for anti-rubella antibodies was 98.9% after the MMR vaccination. There was no difference in the seroconversion rates in the subjects receiving the MMR vaccine either from the single-dose or the multi-dose formulation. The Geometric Mean Titre (GMT) of anti-measles, anti-mumps and anti-rubella antibodies was 3154.0 mIU/mL, 90.6 EU/mL and 141.7 IU/mL, respectively. The vaccine was well tolerated, 28 subjects (out of 123) reported 43 adverse events during the study (adverse event rate of 21.8%). The most common adverse event reported during the study was fever in 19 subjects (15.4%) followed by rash and rhinorrhoea in five subjects (4.1%) each. Conclusion: The results of this phase II clinical trial show that both the single-dose and the multi-dose formulation of the novel MMR vaccine are immunogenic and well tolerated by healthy paediatric subjects aged 15-18 months.
Authors and Affiliations
Rajesh Joshi, Neeta Hanumante, Uma Nayak, Shalaka Agarkhedkar, Paresh Thakkar, Jayesh Sanmukhani, Ravindra Mittal
Keywords
Related Articles
- EP ID EP523933
- DOI 10.7860/JCDR/2018/29855.11125
- Views 64
- Downloads 0
Co-infection of Dengue and Leptospirosis in Patients Presenting to a Tertiary Care Hospital with Acute Febrile Illness: A Cross-sectional Study
ABSTRACT Introduction: Dengue and Leptospirosis are emerging important public health problems in India. While Dengue is a vector borne viral infection transmitted by Aedes mosquitoes, Leptospirosis is a zoonosis caused b...
Histopathological Pattern of Prostate Carcinoma using New Grading System in a Tertiary Centre of Saudi Arabia
ABSTRACT Introduction: Gleason grading of prostate carcinoma has undergone significant revisions and the new grading system has been accepted by the World Health Organisation (WHO) 2016, which is known to avoid confusion...
A Case Report of Ureteral Triplication with Contralateral Duplication-A Rare Anomaly with Difficult Diagnosis and Treatment
ABSTRACT Ureteral triplication is a rare congenital anomaly of the urinary tract with around 100 reported cases in English literature. Rarer is the presence of bilateral ectopic ureter with it. Here, a case of a young fe...
Osseous Metaplasia of Juvenile Polyp
ABSTRACT Bone formation in the gastrointestinal tract is very uncommon. We came across a case of 12-year-old boy with rectal bleeding because of rectal polyp. Snare resection of that polyp was done, and pathology report...
Anti-inflammatory and Analgesic Activities of Topical Formulations of Pterocarpus Santalinus Powder in Rat Model of Chronic Inflammation
Introduction: The incidence of arthritis is quite high and there is a need for the search of natural products to halt the progression of disease or provide symptomatic relief without significant adverse effects. Aim: Thi...